U.S. CDC alarmed at rise of drug-resistant gonorrhea

By Will Dunham

WASHINGTON (Reuters) - Gonorrhea in the United States is now resistant to all but one class of antibiotic drugs, threatening doctors' ability to treat the common sexually transmitted disease, officials said on Thursday.

The U.S. Centers for Disease Control and Prevention said it will no longer recommend antibiotics called fluoroquinolones to combat the bacterial disease because of the emergence of drug-resistant strains in recent years that thwart them.

The CDC said there is no indication the bacterium that causes gonorrhea is becoming resistant to the remaining class of antibiotics it recommends, known as cephalosporins.

"Although the cephalosporins offer several potential options for treating gonorrhea, the lack of additional classes of antibiotics is a serious concern. There are currently no new drugs for gonorrhea in the drug development pipeline," Dr. John Douglas, director of the CDC's Division of Sexually Transmitted Diseases Prevention, told reporters in a conference call.

The CDC released data showing gonorrhea resistant to fluoroquinolones has become widespread among heterosexual men after previously becoming so among homosexual and bisexual men.

"While we have not seen any significant resistance to cephalosporins to date, any emerging resistance would be a significant public health concern. Clearly, there is an urgent need for new, effective medicines to treat gonorrhea as we are running out of options to treat this serious disease," Douglas added.

The CDC said it recommends an injectable drug called ceftriaxone, sold by Roche Pharmaceuticals as Rocephin, to treat genital, anal and throat gonorrhea.

Drug-resistant strains also are on the rise in other parts of the world, the CDC said. All types of bacteria quickly mutate and can develop resistance to medicines designed to kill them.